| المساهمون: |
[de Veas Silva, Jose Luis Garcia] Hosp Univ Virgen Macarena, Dept Clin Biochem, Seville, Spain, [Guitarte, Carmen Bermudo] Hosp Univ Virgen Macarena, Dept Clin Biochem, Seville, Spain, [Valladares, Paloma Menendez] Hosp Univ Virgen Macarena, Dept Clin Biochem, Seville, Spain, [de Veas Silva, Jose Luis Garcia] Complejo Hosp Univ Granada, Dept Immunol, Granada, Spain, [Rojas Noboa, Johanna Carolina] Hosp Univ Virgen Macarena, Dept Hematol, Seville, Spain, [Kestler, Krysta] Hosp Univ Virgen Macarena, Dept Hematol, Seville, Spain, [Millan, Rafael Duro] Hosp Univ Virgen Macarena, Dept Hematol, Seville, Spain, [García de Veas Silva,JL, Bermudo Guitarte,C, Menéndez Valladares,P] Department of Clinical Biochemistry, Hospital Universitario Virgen Macarena, Seville, Spain. [García de Veas Silva,JL] Department of Immunology, Complejo Hospitalario Universitario de Granada, Granada, Spain. [Rojas Noboa,JC, Kestler,K, Duro Millán,R] Department of Hematology, Hospital Universitario Virgen Macarena, Seville, Spain. |
| الوصف: |
Journal Article; BACKGROUND The outcome for patients with Multiple Myeloma (MM) is highly variable, therefore, the existence of robust and easy to determine prognostic markers is extremely important for an efficient management of these patients. Presently, there is a debate about the role of the serum free light chains (sFLC) in the prognosis of MM patients both at diagnosis and after treatment. The aim of this study is to evaluate in a cohort of newly diagnosed MM patients from the Southern area of Spain, the prognostic value of sFLC both at baseline and after treatment. MATERIALS AND METHODS 180 patients with a median age of 69 years were followed-up for a median time of 35 (18-61) months. The sFLC ratio (sFLCR) was calculated using the monoclonal sFLC as numerator. Patients were divided in two groups according to a sFLCR cut-off based on ROC analysis. The primary endpoints were the Overall Survival (OS) and the Progression-free Survival (PFS). Additionally, thirty-six MM patients treated with novel agents (Bortezomib/Dexamethasone) that achieved Complete Response (CR) or stringent CR (sCR) before autologous stem cell transplantation were studied to assess the impact of sCR in Disease Free Survival (DFS) and OS. RESULTS During follow-up there were 72 disease-related deaths. The 5-years OS for the whole group was 51%. However, separate analysis of patients with sFLCR above (group "high") or below (groups "low") the cut-off value of 47 shows an OS of 23% and 73%, respectively (HR = 5.03, 95%CI 2.99-8.50, p3.5 mg/L provided a statistically more significant result for this cohort when compared with the conventional ISS system. The HR for the new model were 2.84 (95% CI, 1.39-5.79, p = 0.004) for patients in stage 2 and 15.39 (95% CI, 6.35-37.33, p |
